Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial in Males With BPH (Enlarged Prostate)

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00029822
First received: January 23, 2002
Last updated: June 6, 2008
Last verified: June 2008
  Purpose

A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH.

  • Free study-related medical care provided.

Condition Intervention Phase
Urinary Retention
Prostatic Hyperplasia
Benign Prostatic Hypertrophy
Drug: Alfuzosin (SL770499)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • occurrence of first episode of acute urinary retention (AUR)

Secondary Outcome Measures:
  • need for benign prostatic hyperplasia (BPH)-related surgery, international prostate symptoms score (IPSS)

Enrollment: 1522
Study Start Date: May 2001
Study Completion Date: March 2005
  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
  • Has been suffering for at least 6 months with any of the following symptoms:
  • daytime or nighttime urinary frequency
  • urgent feeling to urinate
  • difficulty starting urinary stream
  • interruption of urinary stream
  • feeling of incomplete urination
  • Has not had a previous episode of acute urinary retention
  • Has not been diagnosed with prostate cancer
  • Has not had previous prostate surgery
  • Is not an insulin-dependent diabetic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00029822

  Show 54 Study Locations
Sponsors and Collaborators
Sanofi
Investigators
Study Director: ICD CSD Sanofi
  More Information

Additional Information:
Publications:
Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00029822     History of Changes
Other Study ID Numbers: EFC4485, SL770499
Study First Received: January 23, 2002
Last Updated: June 6, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
Acute Urinary Retention
AUR
Benign Prostatic Hyperplasia
Benign Prostatic Hypertrophy
BPH
Enlarged Prostate

Additional relevant MeSH terms:
Hyperplasia
Hypertrophy
Prostatic Hyperplasia
Urinary Retention
Genital Diseases, Male
Pathologic Processes
Pathological Conditions, Anatomical
Prostatic Diseases
Urination Disorders
Urologic Diseases
Alfuzosin
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Urological Agents

ClinicalTrials.gov processed this record on November 23, 2014